2018
DOI: 10.1016/j.bmcl.2017.08.049
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(4 citation statements)
references
References 14 publications
0
4
0
Order By: Relevance
“…Many therapeutic agents are marketed as a pure enantiomer to afford greater efficacy and/or to minimize toxicities (LaPlante et al, 2011b). The racemization of atropisomers due to limitation on bond rotation is time dependent with vastly different half-lives ranging from minutes to years depending on the extent of steric hindrance, electronic influences, temperature, solvents, and conditions (Yang et al, 2018). Many compounds may have rotational hindrance around a single bond, but these are generally very short lived and not detected.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Many therapeutic agents are marketed as a pure enantiomer to afford greater efficacy and/or to minimize toxicities (LaPlante et al, 2011b). The racemization of atropisomers due to limitation on bond rotation is time dependent with vastly different half-lives ranging from minutes to years depending on the extent of steric hindrance, electronic influences, temperature, solvents, and conditions (Yang et al, 2018). Many compounds may have rotational hindrance around a single bond, but these are generally very short lived and not detected.…”
Section: Discussionmentioning
confidence: 99%
“…Therapeutic agents that possess chiral axial centers are much less common than chiral compounds with a stereogenic center. Besides lesinurad, other drugs with a chiral axial center on the market are gossypol and telenzepine, as well as a drug under investigation by Bristol-Myers Squibb (BMS) (BMS-986142) (Eveleigh et al, 1989;Watterson et al, 2016;Yang et al, 2018). BMS-986142 is a reversible inhibitor of Bruton's tyrosine kinase, which is being evaluated in clinical trials for the treatment of autoimmune disorders such as lupus and rheumatoid arthritis.…”
Section: Introductionmentioning
confidence: 99%
“…It caused interest due to identification of new properties of its derivatives. A number of scientific studies demonstrated that, by molecular cross-links with polymeric carriers, gossypol loses its toxic properties while retaining antiviral and immunomodulating effects (19)(20)(21)(22). It is this approach upon which Kagocel development is based.…”
Section: Historymentioning
confidence: 99%
“…There is an increasing interest in using gossypol as antivirus [32][33][34][35][36][37]. Gossypol has many other important effects, where both racemic mixture and enantiomers of gossypol inhibit replicating human immunodeficiency virus-type 1(HIV-1) [29,30]. The in vitro anti-amoebic effects of gossypol were reported against axenic trophozoites from five Entamoeba histolytica strains [31].…”
Section: Introductionmentioning
confidence: 99%